Treatment of fatigue syndrome
OwnerErnir Snorrasoninventor
Life of this patent
Estimating the term…
Abstract
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of fatigue syndromes, including chronic fatigue syndrome, post-infectious fatigue syndromes, fatigue syndromes associated with human immunodeficiency virus (HIV) infection or with preeclampsia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase as opposed to butyryl cholinesterase. Compounds of the invention include galanthamine and galanthamine derivatives.
Claims36
A method for the treatment of a fatigue syndrome, comprising administering, to a patient in need thereof, an effective amount of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor.
A method for the treatment of a fatigue syndrome, comprising administering, to a patient in need thereof, an effective amount of a galanthamine or a galanthamine salt or a galanthamine derivative.
Dependencies are inferred from the claim text.